EpicentRx, Inc. announced that it has entered into an agreement to receive funding from new investor SciClone Pharmaceuticals, Inc. on July 1, 2020. The investor has conditionally agreed to invest in the company. The transaction is subject to certain development, approval, and commercial milestones.